| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
|
N Engl J Med
|
2006
|
5.07
|
|
2
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
|
JACC Cardiovasc Interv
|
2009
|
1.56
|
|
3
|
Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention.
|
J Interv Cardiol
|
2009
|
1.47
|
|
4
|
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.
|
Int J Cardiol
|
2009
|
1.45
|
|
5
|
Antimicrobial peptides: natural effectors of the innate immune system.
|
Semin Immunopathol
|
2007
|
1.43
|
|
6
|
Differential 1-year clinical outcomes for ST-segment elevation myocardial infarction related to stent thrombosis or saphenous vein graft thrombosis.
|
Catheter Cardiovasc Interv
|
2013
|
1.38
|
|
7
|
Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages.
|
Cell Microbiol
|
2011
|
1.17
|
|
8
|
The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils.
|
Eur J Immunol
|
2010
|
1.12
|
|
9
|
Laboratory-acquired brucellosis.
|
Emerg Infect Dis
|
2004
|
1.12
|
|
10
|
Cathelicidin signaling via the Toll-like receptor protects against colitis in mice.
|
Gastroenterology
|
2011
|
1.09
|
|
11
|
Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada.
|
Am Heart J
|
2009
|
1.07
|
|
12
|
CC chemokine ligand 3 overcomes the bacteriocidal and phagocytic defect of macrophages and hastens recovery from experimental otitis media in TNF-/- mice.
|
J Immunol
|
2010
|
0.98
|
|
13
|
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention.
|
Int J Cardiol
|
2010
|
0.95
|
|
14
|
An innate bactericidal oleic acid effective against skin infection of methicillin-resistant Staphylococcus aureus: a therapy concordant with evolutionary medicine.
|
J Microbiol Biotechnol
|
2011
|
0.89
|
|
15
|
Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for non-ST-elevation acute coronary syndromes.
|
Am Heart J
|
2011
|
0.89
|
|
16
|
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
|
Catheter Cardiovasc Interv
|
2007
|
0.89
|
|
17
|
Role of rheolytic thrombectomy in massive pulmonary embolism with contraindication to systemic thrombolytic therapy.
|
EuroIntervention
|
2010
|
0.88
|
|
18
|
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care.
|
Cutis
|
2013
|
0.85
|
|
19
|
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
|
Int J Cardiol
|
2008
|
0.85
|
|
20
|
Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trial.
|
Am Heart J
|
2007
|
0.85
|
|
21
|
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
|
Eur Heart J
|
2008
|
0.85
|
|
22
|
Effect on bleeding, time to revascularization, and one-year clinical outcomes of the radial approach during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
|
Am J Cardiol
|
2010
|
0.85
|
|
23
|
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.
|
Cutis
|
2014
|
0.83
|
|
24
|
Demographics, treatment and outcome of acute coronary syndromes: 17 years of experience in a specialized cardiac centre.
|
Can J Cardiol
|
2006
|
0.83
|
|
25
|
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents.
|
Cutis
|
2013
|
0.83
|
|
26
|
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
|
Am Heart J
|
2010
|
0.82
|
|
27
|
Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
|
Arch Intern Med
|
2007
|
0.82
|
|
28
|
The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).
|
Can J Cardiol
|
2011
|
0.81
|
|
29
|
Relation between previous angiotensin-converting enzyme inhibitor use and in-hospital outcomes in acute coronary syndromes.
|
Am J Cardiol
|
2011
|
0.81
|
|
30
|
Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes.
|
Am Heart J
|
2009
|
0.81
|
|
31
|
Prognostic significance of elevated creatine kinase MB after coronary bypass surgery and after an acute coronary syndrome: results from the GUARDIAN trial.
|
J Thorac Cardiovasc Surg
|
2003
|
0.81
|
|
32
|
Canadian Cardiovascular Society position statement on radiation exposure from cardiac imaging and interventional procedures.
|
Can J Cardiol
|
2013
|
0.80
|
|
33
|
Reperfusion strategies and outcomes of ST-segment elevation myocardial infarction patients in Canada: observations from the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE).
|
Can J Cardiol
|
2011
|
0.80
|
|
34
|
Use and timing of coronary angiography and associated in-hospital outcomes in Canadian non-ST-segment elevation myocardial infarction patients: insights from the Canadian Global Registry of Acute Coronary Events.
|
Can J Cardiol
|
2013
|
0.80
|
|
35
|
Evaluation of left ventricular ejection fraction in non-ST-segment elevation acute coronary syndromes and its relationship to treatment.
|
Am Heart J
|
2010
|
0.79
|
|
36
|
Finite element modeling of a progressively expanding shape memory stent.
|
J Biomech
|
2005
|
0.79
|
|
37
|
Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial.
|
J Am Coll Cardiol
|
2016
|
0.78
|
|
38
|
Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension.
|
Am Heart J
|
2013
|
0.78
|
|
39
|
Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 4: a status report on physical modalities and devices.
|
Cutis
|
2014
|
0.77
|
|
40
|
Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes.
|
Can J Cardiol
|
2011
|
0.76
|
|
41
|
Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study.
|
Eur Heart J
|
2009
|
0.76
|
|
42
|
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
|
Can J Cardiol
|
2006
|
0.75
|
|
43
|
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies.
|
Cutis
|
2014
|
0.75
|
|
44
|
The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
|
Am Heart J
|
2008
|
0.75
|
|
45
|
Endocardial cryotherapy as a novel strategy of improving myocardial perfusion in a patient with severe coronary artery disease.
|
Catheter Cardiovasc Interv
|
2003
|
0.75
|
|
46
|
Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease.
|
Int J Cardiol
|
2013
|
0.75
|
|
47
|
Internal thoracic artery dissection: a proposed mechanistic explanation.
|
JACC Cardiovasc Interv
|
2013
|
0.75
|
|
48
|
In vivo measurement of coronary circulation angiotensin-converting enzyme activity in humans.
|
Am J Physiol Heart Circ Physiol
|
2003
|
0.75
|
|
49
|
Multimodal imaging study of a thrombosed right coronary artery aneurysm.
|
Rev Esp Cardiol
|
2009
|
0.75
|